NASDAQ:HOLX - Hologic Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
Get Started
$39.46 -1.00 (-2.47 %)
(As of 06/25/2018 11:55 AM ET)
Previous Close$40.20
Today's Range$39.46 - $40.41
52-Week Range$35.10 - $46.54
Volume37,824 shs
Average Volume2.15 million shs
Market Capitalization$11.05 billion
P/E Ratio19.67
Dividend YieldN/A
Beta0.86
Hologic logoHologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health. It offers Aptima family of assays, target capture/nucleic acid extraction technology, transcription-mediated amplification technology, hybridization protection and dual kinetic assay technologies, instrumentation, Invader chemistry platform, ThinPrep system, and rapid fetal fibronectin test products. It also provides breast imaging and related products, and accessories comprising digital and film-based mammography systems; computer-aided detection for mammography; minimally invasive breast biopsy devices; breast biopsy site markers; and breast biopsy guidance systems. In addition, it offers Dimensions platform, a mammography gantry for 2D and tomosynthesis image acquisition and display; C-View and Intelligent 2D, a software product that provides 2D images; Selenia digital mammography platform; and SecurView Workstation. Further, it provides SculpSure, MonaLisa Touch, Vectus diode, and Cellulaze laser devices; PicoSure and Icon aesthetic systems; MedLite, RevLite, Cynergy, Elite, and SmartLipo products; and system components. Additionally, it offers NovaSure system to treat women suffering from abnormal uterine bleeding; MyoSure system for the hysteroscopic removal of fibroids; discovery and horizon X-ray bone densitometers that assess the bone density of fracture sites; and mini C-arm imaging systems to perform minimally invasive surgical procedures on a patient's extremities, such as the hand, wrist, knee, foot, and ankle. The company sells its products through direct sales and service forces, and a network of independent distributors and sales representatives. Hologic, Inc. was founded in 1985 and is headquartered in Marlborough, Massachusetts.

Receive HOLX News and Ratings via Email

Sign-up to receive the latest news and ratings for HOLX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry X-ray apparatus & tubes
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:HOLX
CUSIP43644010
Webwww.hologic.com
Phone508-263-2900

Debt

Debt-to-Equity Ratio1.13
Current Ratio1.26
Quick Ratio0.98

Price-To-Earnings

Trailing P/E Ratio19.67
Forward P/E Ratio17.70
P/E Growth1.91

Sales & Book Value

Annual Sales$3.06 billion
Price / Sales3.52
Cash Flow$3.5743 per share
Price / Cash11.04
Book Value$9.93 per share
Price / Book3.97

Profitability

EPS (Most Recent Fiscal Year)$2.03
Net Income$755.50 million
Net Margins-4.15%
Return on Equity20.86%
Return on Assets7.51%

Miscellaneous

Employees6,233
Outstanding Shares273,010,000

The Truth About Cryptocurrencies

Hologic (NASDAQ:HOLX) Frequently Asked Questions

What is Hologic's stock symbol?

Hologic trades on the NASDAQ under the ticker symbol "HOLX."

How were Hologic's earnings last quarter?

Hologic, Inc. (NASDAQ:HOLX) posted its earnings results on Wednesday, May, 2nd. The medical equipment provider reported $0.53 earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of $0.53. The medical equipment provider earned $789.30 million during the quarter, compared to analyst estimates of $781.23 million. Hologic had a positive return on equity of 20.86% and a negative net margin of 4.15%. The company's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the previous year, the company earned $0.50 EPS. View Hologic's Earnings History.

What guidance has Hologic issued on next quarter's earnings?

Hologic updated its FY18 earnings guidance on Wednesday, May, 2nd. The company provided earnings per share guidance of $2.22-2.27 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.26. The company issued revenue guidance of $3.18-3.21 billion, compared to the consensus revenue estimate of $3.25 billion.Hologic also updated its Q3 guidance to $0.55-0.57 EPS.

What price target have analysts set for HOLX?

14 brokerages have issued 12-month price objectives for Hologic's stock. Their forecasts range from $39.00 to $52.00. On average, they anticipate Hologic's share price to reach $45.00 in the next year. View Analyst Ratings for Hologic.

What are Wall Street analysts saying about Hologic stock?

Here are some recent quotes from research analysts about Hologic stock:
  • 1. BTIG Research analysts commented, "in the New Year; Maintain Buy, $17 PT Our thesis is unchanged as SPNE put up solid results in 1Q18. Recall that SPNE has been transitioning the US spinal hardware business from legacy products to newer products that should (and are) growing at a faster pace, namely Mariner and Shoreline. While it has taken a few quarters, SPNE now has ~45% (up from ~24% in 1Q17) of its US spinal implant revenue coming from newer products. Combined with a growing exclusive distributor base, results came in slightly above expectations at $33.2M (+4.0%) relative to BTIG/Consensus of $32.5M/$32.7M respectively. In addition, orthobiologics continues to grow in the MSD from the strength of the portfolio, +5.2% WW, +4.9% US. SPNE is launching multiple products in both categories through FY18 (including a lateral system, Regatta, in 3Q18) while also developing instrumentation that works with navigation access. Collectively, the business continues its positive progression, the portfolio continues to build, and growth should increase to the MSD to HSD in 2H18. While macro spine dynamics remain soft, SPNE is a share taker (even if it is at a smaller scale than others). We maintain our Buy rating and $17 PT." (5/6/2018)
  • 2. Needham & Company LLC analysts commented, "FDA’s latest monthly Mammography Quality Standards Act (MQSA) statistics were published on 5/1/18. The number of digital breast tomosynthesis (DBT) units increased by 199 during April which represents a 165.3% Y/ Y increase. DBT unit penetration increased to 31.8% from 31.1% last month and facility penetration increased to 49.6% from 48.1% last month. More importantly, DBT units placements are up 29.4% year-to-date (YTD) in 2018 vs. 2017. Assuming that HOLX is at least holding mammography market share, we believe its Breast Health business could accelerate some in 2018 given the strong YTD US mammography placements. We note that HOLX’s 3D mammography sales are less than 13% of its total sales." (5/1/2018)
  • 3. According to Zacks Investment Research, "Over the past three months, Hologic has been underperforming its industry. The company's  blood screening divestiture continues to impede growth. Foreign currency headwinds and a competitive landscape also continue to pose challenges for the company. On a positive note, Hologic has been witnessing strength in the Molecular Diagnostics. Moreover,  growth across all geographical regions buoys optimism. Buoyed on differentiated products, Breast Health has been performing well. We are upbeat about the recent CE Mark approval for Brevera breast biopsy system. Also, the PMA approval for the Aptima HBV Quant Assay for quantitation of hepatitis B viral load on the fully automated Panther system buoys optimism. Hologic’s strong cash position is encouraging." (4/30/2018)

Who are some of Hologic's key competitors?

Who are Hologic's key executives?

Hologic's management team includes the folowing people:
  • Mr. Stephen P. MacMillan, Chairman, CEO & Pres (Age 54)
  • Mr. Robert W. McMahon, Chief Financial Officer (Age 49)
  • Mr. John M. Griffin, Gen. Counsel (Age 57)
  • Mr. Peter J. Valenti III, Division Pres of Breast & Skeletal Health Solutions (Age 55)
  • Mr. Eric B. Compton, Consultant (Age 53)

Has Hologic been receiving favorable news coverage?

News stories about HOLX stock have been trending somewhat positive recently, according to Accern Sentiment. Accern identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Hologic earned a media sentiment score of 0.17 on Accern's scale. They also assigned news stories about the medical equipment provider an impact score of 44.64 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Who are Hologic's major shareholders?

Hologic's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.33%), Victory Capital Management Inc. (2.00%), Wells Fargo & Company MN (1.76%), Northern Trust Corp (1.27%), Dimensional Fund Advisors LP (0.84%) and Guggenheim Capital LLC (0.64%). Company insiders that own Hologic stock include Allison P Bebo, Charles J Dockendorff, Elaine Ullian, Karleen Marie Oberton, Lawrence M Levy, Namal Nawana, Nancy Leaming, Peter J Valenti III and Sally Crawford. View Institutional Ownership Trends for Hologic.

Which major investors are selling Hologic stock?

HOLX stock was sold by a variety of institutional investors in the last quarter, including Mackay Shields LLC, Allianz Asset Management GmbH, Allianz Asset Management GmbH, BlackRock Inc., Wells Fargo & Company MN, The Manufacturers Life Insurance Company, JPMorgan Chase & Co. and Thrivent Financial for Lutherans. Company insiders that have sold Hologic company stock in the last year include Allison P Bebo, Elaine Ullian, Karleen Marie Oberton, Lawrence M Levy and Peter J Valenti III. View Insider Buying and Selling for Hologic.

Which major investors are buying Hologic stock?

HOLX stock was bought by a variety of institutional investors in the last quarter, including Amundi Pioneer Asset Management Inc., Natixis, Dimensional Fund Advisors LP, Stevens Capital Management LP, NS Partners Ltd, BNP Paribas Arbitrage SA, BB&T Securities LLC and Verition Fund Management LLC. Company insiders that have bought Hologic stock in the last two years include Charles J Dockendorff and Namal Nawana. View Insider Buying and Selling for Hologic.

How do I buy shares of Hologic?

Shares of HOLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Hologic's stock price today?

One share of HOLX stock can currently be purchased for approximately $39.46.

How big of a company is Hologic?

Hologic has a market capitalization of $11.05 billion and generates $3.06 billion in revenue each year. The medical equipment provider earns $755.50 million in net income (profit) each year or $2.03 on an earnings per share basis. Hologic employs 6,233 workers across the globe.

How can I contact Hologic?

Hologic's mailing address is 250 CAMPUS DRIVE, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at 508-263-2900 or via email at [email protected]


MarketBeat Community Rating for Hologic (HOLX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  600 (Vote Outperform)
Underperform Votes:  413 (Vote Underperform)
Total Votes:  1,013
MarketBeat's community ratings are surveys of what our community members think about Hologic and other stocks. Vote "Outperform" if you believe HOLX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HOLX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/25/2018 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.